## Olaf Eickmeier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8538907/publications.pdf

Version: 2024-02-01

22 589
papers citations

687220 13 h-index 23 g-index

24 all docs 24 docs citations 24 times ranked 1104 citing authors

#	Article	IF	CITATIONS
1	Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. Cytokine, 2010, 50, 152-157.	1.4	108
2	Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2013, 12, 431-439.	0.3	65
3	The Chitinase-Like Protein YKL-40 Modulates Cystic Fibrosis Lung Disease. PLoS ONE, 2011, 6, e24399.	1.1	44
4	Oxidative stress-driven pulmonary inflammation and fibrosis in a mouse model of human ataxia-telangiectasia. Redox Biology, 2018, 14, 645-655.	3.9	43
5	Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis. Mycopathologia, 2018, 183, 21-32.	1.3	43
6	Airway inflammation in children and adolescents with bronchiolitis obliterans. Cytokine, 2015, 73, 156-162.	1.4	42
7	Pro-resolving lipid mediator Resolvin D1 serves as a marker of lung disease in cystic fibrosis. PLoS ONE, 2017, 12, e0171249.	1.1	42
8	Anti-inflammatory effects of montelukast in mild cystic fibrosis. Annals of Allergy, Asthma and Immunology, 2002, 89, 599-605.	0.5	31
9	<i>CXCR1</i> and <i>CXCR2</i> haplotypes synergistically modulate cystic fibrosis lung disease. European Respiratory Journal, 2012, 39, 1385-1390.	3.1	27
10	Airway inflammation in mild cystic fibrosis. Journal of Cystic Fibrosis, 2017, 16, 107-115.	0.3	24
11	Immune Response, Diagnosis and Treatment of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis Lung Disease. Current Pharmaceutical Design, 2013, 19, 3669-3678.	0.9	20
12	Altered mucosal immune response after acute lung injury in a murine model of Ataxia Telangiectasia. BMC Pulmonary Medicine, 2014, 14, 93.	0.8	16
13	Tiotropium add-on therapy is safe andÂreduces seasonal worsening in paediatricÂasthma patients. European Respiratory Journal, 2019, 53, 1801824.	3.1	14
14	Clinical relevance of Aspergillus fumigatus sensitization in cystic fibrosis. Clinical and Experimental Allergy, 2020, 50, 325-333.	1.4	11
15	Comparison of the Lung Clearance Index in Preschool Children With Primary Ciliary Dyskinesia and Cystic Fibrosis. Chest, 2022, 162, 534-542.	0.4	11
16	CXCR4 <sup>+</sup> granulocytes reflect fungal cystic fibrosis lung disease. European Respiratory Journal, 2015, 46, 395-404.	3.1	10
17	Effects of long-term treatment with Montelukast in mild cystic fibrosis. Respiratory Medicine, 2007, 101, 684.	1.3	8
18	Fungi in Cystic Fibrosis: Recent Findings and Unresolved Questions. Current Fungal Infection Reports, 2015, 9, 1-5.	0.9	8

#	Article	IF	CITATIONS
19	Inflammation biomarkers in sputum for clinical trials in cystic fibrosis: current understanding and gaps in knowledge. Journal of Cystic Fibrosis, 2022, 21, 691-706.	0.3	8
20	Coil embolisation for massive haemoptysis in cystic fibrosis. BMJ Open Respiratory Research, 2021, 8, e000985.	1.2	6
21	Patient Science: Citizen Science Involving Chronically Ill People as Co-Researchers. Journal of Participatory Research Methods, 2022, 3, .	0.2	5
22	Impact of a Gap Junction Protein Alpha 4 Variant on Clinical Disease Phenotype in F508del Homozygous Patients With Cystic Fibrosis. Frontiers in Genetics, 2020, 11, 570403.	1.1	1